CP3’s own Dr. Tim Anderson was interviewed for a New York Times story examining recent trends in the use of GLP-1 weight-loss medications among older adults and the factors driving changes in patient behavior and outcomes. The article explores how these widely discussed therapies—originally developed for diabetes and now often used for weight management—are affecting older populations, including common side effects such as gastrointestinal symptoms and considerations for sustained use. Dr. Anderson provided expert insight into these issues, helping to contextualize the clinical and real-world implications of GLP-1 prescribing and discontinuation in this growing area of medication use research.